FDA approves one drug for irritable bowel syndrome but suspends another.
D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002908:Chronic Disease; D017277:Drug Approval; D004335:Drug and Narcotic Control; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D000068238:Lubiprostone; D014481:United States; D014486:United States Food and Drug Administration
D005765:Gastrointestinal Agents; D007211:Indoles; C105050:tegaserod; D000068238:Lubiprostone; D000527:Alprostadil